Sourcing Exosomes in Minnesota
Licensed Minnesota practices order Kimera exosome material from ExaVeyra for topical aesthetic use, shipped frozen from Florida with a Certificate of Analysis and lot traceability on every vial. Minnesota buyers need their own professional license and NPI; the wholesale drug distributor license is the supplier’s obligation, not the purchaser’s.
Minnesota is a full practice authority state: a nurse practitioner who completes 2,080 hours within a collaborative agreement then evaluates and orders within their own scope, with no ongoing physician protocol. A 2026 amendment loosened where those hours may be earned and who may collaborate, so the details below reflect the law as of 1 August 2026.
At a glance
| Question | Answer |
|---|---|
| Does ExaVeyra ship to Minnesota? | Yes. Shipped frozen from Florida, as we do to all 50 states |
| Cold-chain shipping from Florida | Overnight shipping; arrival can take 1 to 3 business days |
| State regenerative-medicine statute | None |
| Does that statute reach exosomes? | No. Its definition is written around cells; exosomes are acellular and governed federally |
| Physician delegation required to hand off medical acts | No |
| Who holds the licensure to ship into the state | The pharmacy partner and the tissue bank that ship, not the purchasing practice |
| What ExaVeyra supplies here | Kimera exosome material. Compounded preparations are not available in this state at this time |
| Last reviewed | 16 October 2026 |
Ordering from Minnesota
ExaVeyra ships to licensed practices in all 50 states, Minnesota included. Licensure for shipping into the state is held by the entities that ship: our 503A pharmacy partner holds nonresident pharmacy licenses in 33 jurisdictions, including Puerto Rico, and exosome material ships from a registered tissue bank licensed to ship to all 50 states and Puerto Rico. Your practice orders against its own professional license and NPI and needs no wholesale permit to purchase.
What your practice provides
- An active Minnesota professional license in good standing, verifiable through the license lookup of the Board of Medical Practice or the Board of Nursing at mn.gov/boards.
- A valid NPI, which ExaVeyra verifies at account setup.
- A signed professional-use acknowledgment on file for exosome material.
- A Minnesota resale exemption certificate (Form ST3) if the practice is purchasing for resale rather than for use in its own operations.
How the state permits wholesale distribution
Minnesota licenses wholesale drug distributors through the Board of Pharmacy, consistent with the federal Drug Supply Chain Security Act licensing standards in 21 U.S.C. 360eee-2. The license is per facility: a separate license is required for each facility located outside Minnesota from which drugs are shipped into the state, and an out-of-state facility must also show the Board proof of licensure in its home state or by the FDA. The regime covers drugs; it does not extend to devices. The license sits with the distributor, not with the purchasing practice.
Minn. Stat. 151.47 · Minnesota Board of Pharmacy
Minnesota regenerative-medicine law
Minnesota has not enacted a statute specific to stem cell or regenerative therapies. Practice in this area is governed by the state's general medical practice and professional licensing rules, alongside federal law.
Minnesota has no statute authorizing, conditioning, or requiring disclosure for unapproved regenerative therapy in a clinical setting, so federal law is the only layer that addresses it. The phrase "regenerative medicine" does appear in Minnesota law, which causes regular confusion: Laws of Minnesota 2014, chapter 312, article 1, section 4 appropriates state money to the collaborative partnership between the University of Minnesota and the Mayo Clinic for regenerative medicine research, clinical translation, and commercialization. That is a research funding program, not an authorization to practice, and it neither permits nor conditions any clinical service. Practice in this area is governed by the Medical Practice Act, the Nurse Practice Act, and the boards that administer them, alongside federal law.
How this applies to exosomes
Minnesota has not enacted a stem cell authorization law like Florida, Texas, or Georgia, a disclosure law like California, or a documentation statute like Tennessee. The regenerative medicine appropriation to the University of Minnesota and Mayo Clinic partnership is sometimes cited as though it were a practice law; it funds research and does nothing to authorize or restrict a clinical service. There is therefore no Minnesota definition to read acellular extracellular vesicles into or out of. Exosome products in Minnesota are governed by federal law, under which no exosome product has been approved by the FDA for administration to humans. ExaVeyra supplies Kimera material for topical aesthetic use by licensed practitioners, with full COA and lot documentation.
Who can handle product in a Minnesota practice
Because experienced APRNs hold independent authority in Minnesota, there are two workable structures rather than one. An APRN-led practice can evaluate and order within APRN scope with no physician protocol, which is why no medical director is required by default. A physician-led practice delegates conventionally, and a collaborating or directing physician is still needed where a procedure falls outside APRN scope, during a new APRN’s 2,080 collaborative hours, or where a payer requires one.
| Role | Scope under state law |
|---|---|
| MD / DO | Physicians licensed by the Minnesota Board of Medical Practice may perform medical acts within their scope and are the source of delegation to staff who do not hold independent authority. |
| NP / APRN | Minnesota grants APRNs full practice authority. Under Minn. Stat. 148.211, subd. 1c, a nurse practitioner or clinical nurse specialist practices for at least 2,080 hours within a collaborative agreement and then practices independently, evaluating, ordering, and prescribing within APRN scope. Chapter 115, Article 11, effective 1 August 2026, removed the requirement that those hours be earned in a hospital or integrated clinical setting and allows the collaborator to be a physician or an APRN with at least three years of practice. |
| PA | Physician assistants follow the mirror-image structure under Minn. Stat. 147A.02: at least 2,080 hours within a collaborative agreement, after which the PA’s scope is set at the practice level. The collaborating physician need not be physically present if reachable by telecommunication. |
| RN | Registered nurses may perform delegated treatments within their scope and under an order from a provider with authority to issue one, physician or independently practicing APRN alike. An RN does not evaluate the patient or set the treatment plan. |
Good faith examination
Minnesota expects a patient evaluation by a provider with authority to conduct it, and an order, before a delegated treatment is administered. Because APRNs hold full practice authority, that provider can be the APRN. Confirm current expectations with the Minnesota Board of Medical Practice and the Minnesota Board of Nursing, since this area is governed by board interpretation rather than a single statute.
Ownership and clinic licensing
Minnesota’s corporate practice limits come from case law together with the Minnesota Professional Firms Act, Minn. Stat. ch. 319B, under which an entity rendering medical services organizes as a professional firm owned by licensed professionals. The act allows licensed professionals across several health professions to hold ownership rather than drawing a physician-percentage line, and because the doctrine itself is not codified as a bright-line prohibition, published summaries differ on its edges. Treat ownership structure as a question for Minnesota counsel.
Cold chain into Minnesota
Shipments leave Florida frozen under validated temperature monitoring. A package in transit over a weekend waits in the carrier network, so practices in Minnesota order around weekend and holiday closures.
| Metro | County | Notes |
|---|---|---|
| Minneapolis | Hennepin | Largest Minnesota market with broad aesthetic and clinical coverage. |
| St. Paul | Ramsey | Capital half of the Twin Cities market. |
| Edina | Hennepin | Concentrated southwest-metro med spa and dermatology corridor. |
| Rochester | Olmsted | Anchored by the Mayo Clinic, with research-adjacent practices. |
| Duluth | St. Louis | Regional hub serving northeastern Minnesota. |
| St. Cloud | Stearns | Central Minnesota market northwest of the Twin Cities. |
- Minnesota orders of fifteen or more cold-chain units ship free nationwide; see the volume program for current thresholds.
- Every shipment arrives with the manufacturer’s handling instructions and the Certificate of Analysis for its lot.
Wholesale exosome supply by city in Minnesota
Each city page covers local receiving conditions, delivery disruptions and business license rules for Minnesota practices in that area.
Practice types we supply in Minnesota
Minnesota licensing and verification
Minnesota Board of Medical Practice
Minnesota Board of Nursing
Licenses APRNs, who hold full practice authority after the collaborative hours.
Minnesota Board of Pharmacy
Licenses wholesale drug distributors per facility, including out-of-state facilities shipping in.
Minnesota Department of Revenue
Sales tax registration and resale exemption certificates.
Minnesota sourcing questions
- Does Minnesota have a stem cell law?
- Not a practice law. The regenerative medicine language in Minnesota law is an appropriation: Laws of Minnesota 2014, chapter 312 funds the University of Minnesota and Mayo Clinic partnership for regenerative medicine research, clinical translation, and commercialization. It authorizes no clinical service, so exosome products in Minnesota are governed by federal law, under which no exosome product is FDA-approved for administration to humans.
- Can a nurse practitioner run a practice in Minnesota without a physician?
- Yes, once qualified. Under Minn. Stat. 148.211, subd. 1c, a nurse practitioner practices for at least 2,080 hours within a collaborative agreement and then holds full practice authority, evaluating, ordering, and prescribing within APRN scope. Since 1 August 2026 the collaborative hours no longer have to be earned in a hospital or integrated clinical setting, and the collaborator may be a physician or an APRN with at least three years of practice.
- What changed for Minnesota APRNs in 2026?
- Chapter 115, Article 11, effective 1 August 2026, amended Minn. Stat. 148.211. The 2,080-hour postgraduate practice requirement remains, but the hours no longer need to be completed in a hospital or integrated clinical setting, and the collaborative agreement may be with one or more physicians, including physicians licensed in another state or territory, or with APRNs who have at least three years of practice. The APRN provides written evidence of the collaborative experience to the Board of Nursing.
- Does my Minnesota clinic need a wholesale drug distributor license to buy exosomes?
- No. The wholesale drug distributor license under Minn. Stat. 151.47 is held per facility by the distributor shipping into Minnesota, not by the practice buying. Your practice orders against its own professional license and NPI. Licensure for shipping into the state is held by the entities that ship: our 503A pharmacy partner for compounded preparations, and a registered tissue bank licensed to ship to all 50 states and Puerto Rico for exosome material.
- Are exosomes FDA approved?
- No exosome product has been approved by the FDA for administration to humans, and the FDA said so directly in its 2019 public safety notification on exosome products. ExaVeyra supplies Kimera exosome material for topical aesthetic use by licensed practitioners, with a Certificate of Analysis and lot traceability on every vial.
- How long does cold-chain shipping take to Minnesota?
- Ships from Florida by overnight shipping, and arrival can take one to three business days. All exosome shipments travel cold-chain with validated temperature monitoring. A shipment in transit over a weekend waits in the carrier network, so a practice that will be closed orders around the closure.
Sources
Last reviewed 16 October 2026 by ExaVeyra Sciences editorial team. Every claim above links to a primary source.
- Minn. Stat. 151.47, wholesale drug distributor licensing requirements (accessed 16 October 2026)
- Minn. Stat. 148.211, APRN licensure (accessed 16 October 2026)
- Minn. Stat. 147A.02, physician assistant licensure (accessed 16 October 2026)
- Laws of Minnesota 2014, chapter 312 (regenerative medicine research appropriation) (accessed 16 October 2026)
- Minnesota Board of Pharmacy (accessed 16 October 2026)
- Minnesota Board of Medical Practice (accessed 16 October 2026)
- FDA Public Safety Notification on Exosome Products (accessed 16 October 2026)
Scientific literature
Peer-reviewed references, each with its study design and, for human studies, the number of participants, so a reader can judge the weight of a citation without opening it. None is a claim about any product.
- Welsh JA, Goberdhan DCI, O’Driscoll L, et al. Minimal information for studies of extracellular vesicles (MISEV2023): From basic to advanced approaches. Journal of Extracellular Vesicles, 2024. doi:10.1002/jev2.12404 PMID:38326288Clinical guidelinesupports: Defines the field’s current characterization and reporting standard for extracellular vesicles, the benchmark behind the COA and lot documentation this page describes.
- Théry C, Witwer KW, Aikawa E, et al. Minimal information for studies of extracellular vesicles 2018 (MISEV2018): a position statement of the International Society for Extracellular Vesicles and update of the MISEV2014 guidelines. Journal of Extracellular Vesicles, 2018. doi:10.1080/20013078.2018.1535750 PMID:30637094Clinical guidelinesupports: The landmark EV characterization standard that MISEV2023 updates; together they define what a complete exosome characterization package contains.
- Lener T, Gimona M, Aigner L, et al. Applying extracellular vesicles based therapeutics in clinical trials - an ISEV position paper. Journal of Extracellular Vesicles, 2015. doi:10.3402/jev.v4.30087 PMID:26725829Consensus statementsupports: ISEV position on manufacturing and safety documentation for EV-based products in trials, supporting this page’s framing that clinical use runs through regulated research.
These statements have not been evaluated by the FDA. This product is not intended to diagnose, treat, cure, or prevent any disease. There are no FDA-approved exosome products. Biomolecular signaling vesicle products distributed by ExaVeyra Sciences are supplied for topical aesthetic use by licensed practitioners and for laboratory and IND-authorized clinical research, and are not tissue products as defined by FDA guidelines.